| bibliographicCitation |
Koga S, Onishi H, Masuda S, Fujimura A, Ichimiya S, Nakayama K, Imaizumi A, Nishiyama K, Kojima M, Miyoshi K, Nakamura K, Umebayashi M, Morisaki T, Nakamura M. PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor. Translational Oncology. 2021 Sep;14(9):101152. doi: 10.1016/j.tranon.2021.101152. |